List of Excipients in Branded Drug DORZOLAMIDE HCL

Generic Drugs Containing DORZOLAMIDE HCL

Company	Ingredient	NDC	Excipient
Bausch & Lomb Incorporated	dorzolamide hcl	24208-485	BENZALKONIUM CHLORIDE
Bausch & Lomb Incorporated	dorzolamide hcl	24208-485	HYDROXYETHYL CELLULOSE
Bausch & Lomb Incorporated	dorzolamide hcl	24208-485	MANNITOL
Bausch & Lomb Incorporated	dorzolamide hcl	24208-485	SODIUM HYDROXIDE
Bausch & Lomb Incorporated	dorzolamide hcl	24208-485	TRISODIUM CITRATE DIHYDRATE
Bausch & Lomb Incorporated	dorzolamide hcl	24208-485	WATER
A-S Medication Solutions	dorzolamide hcl	50090-2406	AQUA

What are the Most Frequently-Used Excipients in DORZOLAMIDE HCL?

# Of NDCs	Excipient
1	AQUA
4	BENZALKONIUM CHLORIDE
4	HYDROXYETHYL CELLULOSE
4	MANNITOL
1	SODIUM CITRATE
4	SODIUM HYDROXIDE
3	TRISODIUM CITRATE DIHYDRATE

Dorzolamide HCl Excipient Strategy and Commercial Opportunities

Last updated: August 3, 2026

Dorzolamide hydrochloride is an established ophthalmic carbonic anhydrase inhibitor used primarily for ocular hypertension and open-angle glaucoma. The active ingredient is off-patent, and commercial value now depends on formulation differentiation, preservative strategy, manufacturing efficiency, device compatibility, and access to specialty ophthalmology channels rather than on active-ingredient exclusivity.

The core formulation is an aqueous multidose ophthalmic solution containing dorzolamide HCl, mannitol, hydroxyethyl cellulose, citrate buffer, sodium hydroxide, benzalkonium chloride, and purified water. The strongest development opportunities are preservative-free multidose delivery, lower-irritation preserved products, fixed-dose combinations, unit-dose packaging, and improved adherence through viscosity and delivery optimization.

What is dorzolamide HCl used for?

Dorzolamide HCl is a topical carbonic anhydrase inhibitor that reduces aqueous humor production and lowers intraocular pressure. FDA-approved indications include:

• Elevated intraocular pressure in ocular hypertension
• Open-angle glaucoma
• Use as monotherapy or adjunctive therapy with ophthalmic beta blockers

The reference product is Trusopt, originally commercialized by Merck. Dorzolamide is also marketed in combination with timolol as Cosopt and in generic products. The usual dorzolamide ophthalmic solution concentration is 2%, equivalent to 20 mg/mL of dorzolamide.

Attribute	Dorzolamide HCl ophthalmic solution
Therapeutic class	Topical carbonic anhydrase inhibitor
Typical strength	2% w/v
Dosage form	Sterile aqueous ophthalmic solution
Primary indications	Ocular hypertension and open-angle glaucoma
Administration	Usually one drop three times daily as monotherapy
Combination use	Commonly combined with timolol or prostaglandin analogues
FDA pathway for generics	Abbreviated New Drug Application
Biosimilar relevance	None; dorzolamide is a small molecule
Primary formulation issue	Ocular tolerability and preservative exposure

FDA labeling identifies dorzolamide HCl ophthalmic solution as a sterile, isotonic, buffered topical product. The reference formulation uses benzalkonium chloride as a preservative and hydroxyethyl cellulose to control viscosity [1].

What excipients are used in dorzolamide HCl ophthalmic products?

The reference dorzolamide formulation uses a relatively conventional ophthalmic excipient system.

Excipient	Primary function	Commercial and technical considerations
Hydroxyethyl cellulose	Viscosity modifier and retention aid	Can improve ocular residence time but may affect drop formation and visual blurring
Mannitol	Tonicity agent	Supports isotonicity and may help manage solution feel
Sodium citrate dihydrate	Buffer component	Controls pH and supports chemical stability
Sodium hydroxide	pH adjustment	Used to establish the target formulation pH
Benzalkonium chloride	Antimicrobial preservative	Effective and inexpensive but associated with ocular-surface tolerability concerns
Purified water	Vehicle	Must meet ophthalmic-grade water and microbial-control requirements

The product’s pH is generally maintained in the mildly acidic range, approximately pH 5.5 to 5.9, depending on the specific product and label. Dorzolamide HCl is sufficiently water soluble for solution development, which reduces the need for solubilizers, cosolvents, surfactants, or complexation systems.

The formulation design challenge is therefore less about dissolving the active ingredient and more about balancing pH, buffering capacity, tonicity, viscosity, preservative effectiveness, container compatibility, and patient comfort.

How should an excipient system for dorzolamide HCl be designed?

A commercial formulation should start with the reference excipient architecture but optimize one or more clinically relevant attributes.

pH and buffer strategy

Citrate is a logical buffer because it is already associated with the reference product and is widely accepted in ophthalmic products. The buffer should be kept sufficiently low to avoid unnecessary buffering of the ocular surface while maintaining pH throughout shelf life.

Key development controls include:

• Dorzolamide assay and degradation products across the pH range
• Precipitation risk after dilution with tears
• Container-closure interaction
• Preservative activity at the final pH
• Ocular comfort during repeated dosing

Excessive buffer capacity can increase stinging and may reduce comfort even when the final pH is within the acceptable formulation range.

Tonicity strategy

Mannitol is the principal tonicity agent in the reference formulation. Sodium chloride could be evaluated, but direct substitution may alter ionic strength, preservative behavior, and ocular sensation. A mixed tonicity system using mannitol and sodium chloride may support a narrower osmolality target, but it would require fresh compatibility and stability studies.

For a generic formulation, excipient selection should avoid unnecessary departures from the reference product unless the change creates a clear commercial or regulatory advantage.

Viscosity strategy

Hydroxyethyl cellulose provides modest viscosity enhancement. It can increase ocular residence time and reduce rapid drainage, but high viscosity can cause:

• Transient blurred vision
• Inconsistent drop size
• More difficult bottle squeezing
• Increased nozzle residual volume
• Greater variability in delivered dose

A useful development range would evaluate low-viscosity, reference-like products against moderately enhanced-viscosity products. The best commercial profile is usually a viscosity increase that improves retention without creating a noticeable optical or dispensing penalty.

Alternative polymers, including hypromellose, povidone, carbomers, and other cellulose derivatives, could support differentiated products. Each introduces distinct risks involving haze, pH dependence, rheology, sterilization, extractables, and preservative distribution.

Preservative strategy

Benzalkonium chloride is the established preservative for dorzolamide ophthalmic solution. It provides manufacturing and packaging advantages because it is familiar to regulators, suppliers, and contract manufacturers.

Its commercial disadvantage is repeated ocular-surface exposure. Preservative-free products may have greater appeal for patients with chronic glaucoma, dry-eye symptoms, ocular-surface disease, or multiple daily ophthalmic medications.

Three preservative strategies are commercially relevant:

Strategy	Advantages	Main barriers
Benzalkonium chloride	Low cost, established efficacy, conventional multidose bottle	Ocular-surface tolerability and chronic-use concerns
Alternative preservative	May improve tolerability while retaining multidose packaging	New antimicrobial and compatibility package
Preservative-free	Strong differentiation for chronic therapy	Device cost, microbial-control burden, packaging complexity

Alternative preservative systems may include polyquaternium-based systems or oxidative preservative technologies. They should not be treated as simple drop-in replacements. The regulatory package must establish antimicrobial effectiveness, preservative concentration uniformity, container compatibility, and stability after opening.

What preservative-free formulations could be developed?

Preservative-free dorzolamide HCl has the clearest excipient-led differentiation opportunity.

Preservative-free multidose bottle

A preservative-free multidose product generally requires a valve-controlled or airless dispensing system that limits microbial ingress. The formulation may remain close to the reference product, with benzalkonium chloride removed and the container-closure system redesigned.

Commercial benefits include:

• Positioning for chronic users
• Reduced preservative exposure
• Potential preference among ophthalmologists treating ocular-surface disease
• Premium pricing relative to standard generic bottles

The main barriers are device qualification, microbial ingress testing, delivered-volume consistency, priming behavior, residual volume, and cost of goods.

Unit-dose containers

Unit-dose packaging can eliminate the need for a preservative and simplify microbial-control arguments. It is suitable for hospital, surgical, institutional, and premium retail channels.

The disadvantages are higher packaging cost, larger packaging volume, more complex logistics, and possible patient inconvenience for long-term daily use. Unit-dose dorzolamide may be most attractive when combined with a broader preservative-free glaucoma portfolio.

Preservative-free fixed-dose combination

A preservative-free dorzolamide and timolol combination could have greater commercial value than dorzolamide monotherapy because fixed-dose combinations reduce bottle burden and may support adherence. The product would require compatibility assessment for both actives, preservative-free multidose or unit-dose packaging, and a clear regulatory strategy.

What formulation patents protect dorzolamide HCl products?

The original dorzolamide composition and ophthalmic formulation patents have expired or are no longer the principal barrier to generic entry in the United States. Trusopt and Cosopt have faced extensive generic competition through the ANDA pathway.

IP category	Current commercial relevance
Dorzolamide active ingredient	Low; established small-molecule compound
Original ophthalmic solution claims	Low after expiration of foundational patents
Dorzolamide-timolol combination	Low for basic active combination; higher for specific delivery or formulation claims
Preservative-free packaging	Potentially meaningful if claims cover a specific system
Device and dispensing system	Potentially meaningful, particularly for multidose preservative-free products
Manufacturing process	Relevant where it improves impurity control, sterility, or scale economics
Method of use	Limited value unless tied to a specific patient population, dosing regimen, or treatment combination

Dorzolamide products do not have biosimilar risk because they are small-molecule drugs. The relevant competition is generic substitution, authorized generics, branded reformulations, and fixed-dose combinations.

Patent strength for a new product would likely depend more on claim scope and enforceability around the delivery system than on the excipient combination alone. Broad claims covering familiar ophthalmic excipients are vulnerable to prior art and obviousness challenges.

When did dorzolamide lose exclusivity?

Dorzolamide’s foundational market exclusivity ended years ago, and generic dorzolamide ophthalmic products are established in the United States and other major markets. The reference product is not protected by biologic exclusivity, and no current exclusivity period comparable to a new chemical entity exclusivity period applies to the original active ingredient.

The commercial timeline is:

Milestone	Status
Original Trusopt approval	Historical
Foundational compound and formulation protection	Expired or commercially non-blocking
Generic dorzolamide entry	Established
Generic dorzolamide-timolol entry	Established
Current competitive barrier	Formulation, device, supply, and channel execution

Exact patent expiration dates vary by patent family, jurisdiction, patent-term adjustment, and listed product. The FDA Orange Book remains the controlling source for current U.S. listed patents and exclusivity information [2].

What is the Orange Book status of dorzolamide HCl?

Dorzolamide HCl ophthalmic products are regulated as small-molecule prescription drugs. Generic products are generally approved under ANDAs that demonstrate pharmaceutical equivalence and bioequivalence or other applicable product-specific requirements.

For a new dorzolamide product, the Orange Book implications differ by strategy:

• A conventional generic solution competes primarily on approval timing, price, supply, and contracting.
• A formulation with a novel delivery system may require a 505(b)(2) application or separate device and drug regulatory analysis.
• A new fixed-dose combination may require product-specific clinical, bioequivalence, or bridging work.
• A preservative-free product may obtain differentiation through labeling and device attributes, but the formulation alone does not automatically create exclusivity.

FDA’s Inactive Ingredient Database can support excipient precedent analysis, but precedent does not replace product-specific safety, stability, sterility, and extractables data [3].

Which companies are challenging or competing with dorzolamide products?

Competition comes from several groups:

1. Generic ophthalmic manufacturers supplying dorzolamide 2%.
2. Generic manufacturers supplying dorzolamide-timolol combinations.
3. Large ophthalmology companies selling alternative glaucoma classes.
4. Device-oriented companies developing preservative-free multidose systems.
5. Contract manufacturers offering sterile ophthalmic fill-finish capacity.

The principal therapeutic competitors include timolol, latanoprost and other prostaglandin analogues, brimonidine, brinzolamide, and fixed-dose combinations. Dorzolamide competes on mechanism, tolerability, price, and combination utility rather than on novel pharmacology.

What commercial opportunities exist for dorzolamide excipient innovation?

Premium preservative-free products

A preservative-free dorzolamide product can target patients with chronic exposure to multiple preserved ophthalmic medicines. A premium position would require a dispensing system that is reliable, easy to use, and cost-effective enough for payer coverage.

Lower-irritation preserved products

A product using a lower-irritation preservative or reduced preservative load could occupy an intermediate position between standard generic dorzolamide and a fully preservative-free product.

Fixed-dose combinations

Dorzolamide-timolol remains the most obvious combination opportunity. Other combinations may be technically and commercially attractive, but each raises compatibility, labeling, and development complexity.

Improved rheology

A modestly more viscous product could reduce drainage and improve dosing persistence. The commercial advantage is strongest if clinical or human-factor data demonstrate less frequent redosing or improved patient handling.

Unit-dose institutional products

Unit-dose packaging may be attractive for hospitals, ambulatory surgery centers, long-term care, and patients requiring preservative avoidance. Manufacturing cost and packaging waste remain the principal constraints.

Emerging-market manufacturing

A simple preserved solution has the lowest cost and broadest manufacturing accessibility. Local production opportunities exist where sterile ophthalmic capacity, reliable container supply, and regulatory compliance are available. Preservative-free systems have higher technical barriers but can create stronger differentiation.

What manufacturing and IP barriers affect dorzolamide products?

The active ingredient is not the main manufacturing barrier. The highest-risk operations are sterile compounding, filtration, aseptic filling, container-closure integrity, and preservative distribution.

Critical controls include:

• Control of dorzolamide-related impurities
• Microbial limits and sterility assurance
• Filter compatibility and adsorption
• Uniformity of preservative concentration
• Extractables and leachables from bottles and tips
• Drop-size consistency
• In-use stability after opening
• Device performance across temperature and orientation ranges

Manufacturing know-how can create practical protection even where patent protection is weak. A formulation that is easy to make at laboratory scale may experience viscosity drift, precipitation, preservative loss, or nozzle fouling during commercial production.

What generic launch risks exist for dorzolamide HCl?

Generic launch risk is moderate for a conventional preserved solution and higher for differentiated delivery systems.

Launch type	Regulatory risk	Commercial risk	Likely differentiation
Standard dorzolamide 2% solution	Low to moderate	High price competition	Supply reliability
Dorzolamide-timolol solution	Moderate	High	Contract access and adherence
Preservative-free unit dose	Moderate to high	Moderate	Ocular-surface positioning
Preservative-free multidose	High	Moderate	Device and premium pricing
Modified-viscosity formulation	Moderate	Moderate	Retention and comfort
Novel combination	High	Moderate to high	Clinical and adherence value

Paragraph IV challenges are historically relevant to branded glaucoma products, but the original dorzolamide market is already genericized. For a new product, the practical IP issue is whether a device, formulation, or method-of-use patent can delay competing follow-on products. Settlement agreements affecting legacy dorzolamide products are unlikely to be the principal determinant of current market access.

How strong is the dorzolamide HCl patent estate?

The original dorzolamide patent estate is commercially weak because the active ingredient and conventional ophthalmic solution have long-established generic competition. A new patent estate could be stronger if it covers:

• A specific preservative-free multidose device
• A validated formulation with defined pH, osmolality, viscosity, and impurity profile
• A stable fixed-dose combination
• A manufacturing process that produces a distinctive impurity profile
• A patient subgroup or dosing regimen with credible clinical support

The weakest strategy is a patent directed only to substituting one familiar ophthalmic excipient for another without a demonstrated technical effect. The strongest strategy combines formulation claims, device claims, process claims, and regulatory exclusivity where available.

Key Takeaways

• Dorzolamide HCl is an off-patent small-molecule ophthalmic drug with established generic competition.
• The reference formulation uses hydroxyethyl cellulose, mannitol, citrate buffer, sodium hydroxide, benzalkonium chloride, and water.
• Preservative-free multidose delivery is the leading excipient and device opportunity.
• Unit-dose packaging can support preservative-free positioning but carries higher cost and logistics burdens.
• Fixed-dose dorzolamide-timolol products offer greater adherence value than dorzolamide monotherapy.
• Conventional excipient substitutions are unlikely to provide strong patent protection without demonstrated technical advantages.
• Manufacturing, microbial control, device performance, and payer access are more important commercial barriers than active-ingredient IP.
• Dorzolamide has no biosimilar exposure. Its competitive risk comes from generics, glaucoma alternatives, and differentiated ophthalmic delivery systems.

FAQs

Is dorzolamide HCl the same as dorzolamide ophthalmic solution?

Dorzolamide HCl is the hydrochloride salt used to manufacture dorzolamide ophthalmic solution. The marketed product is typically labeled by the active moiety and concentration of the hydrochloride formulation.

Can benzalkonium chloride be removed from dorzolamide eye drops?

Yes. A preservative-free product can be developed, but removing benzalkonium chloride requires a new microbial-control strategy, such as unit-dose packaging or a validated multidose dispensing system.

Which excipient controls dorzolamide eye-drop viscosity?

Hydroxyethyl cellulose is the principal viscosity-modifying excipient in the reference formulation. Other cellulose derivatives and ophthalmic polymers may be evaluated, subject to comfort, drop-size, stability, and regulatory requirements.

Does dorzolamide HCl require a biosimilar pathway?

No. Dorzolamide is a chemically synthesized small molecule. Follow-on products use generic drug pathways rather than biosimilar pathways.

Is dorzolamide-timolol more commercially attractive than dorzolamide alone?

Often, yes. The fixed-dose combination can reduce bottle burden and improve adherence, but it requires more complex formulation, bioequivalence, stability, labeling, and commercial development work.

References

1. U.S. Food and Drug Administration. (2023). TRUSOPT: Dorzolamide hydrochloride ophthalmic solution prescribing information. FDA/DailyMed.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.

3. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. FDA Center for Drug Evaluation and Research.